Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

ESMO open

Showing results (131-140 of 2,246) with videos related to

Pageof 225
Sort By:
ESMO Open|October 23, 2018
Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancerJohan F Vansteenkiste
ESMO Open|December 20, 2021
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trialS Branchoux, C L Sofeu, A-F Gaudin, et al.
ESMO Open|November 28, 2021
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study programV Müller, M Banys-Paluchowski, T W P Friedl, et al.
ESMO Open|December 20, 2021
Letter re: 'Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications'W G Sullivan, A J Hatswell
ESMO Open|March 6, 2021
Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancerC Corti, C Criscitiello
ESMO Open|March 6, 2021
Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indicationsM G Krebs, J-Y Blay, C Le Tourneau, et al.
ESMO Open|March 6, 2021
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 studyB Borelli, E Fontana, M Giordano, et al.
ESMO Open|November 15, 2018
Prognostic Nutritional Index: an easy nutritional screening for patients with head and neck cancer?Paolo Bossi
ESMO Open|September 3, 2023
Comment on redefining authorship in the era of artificial intelligence: balancing ethics, transparency, and progressM Scimeca, R Bonfiglio
ESMO Open|September 3, 2023
Unlocking digitally enabled research in oncology: the time is nowM A Franzoi, E Gillanders, I Vaz-Luis
Pageof 225

Showing results (131-140 of 2,246) with videos related to

Sort By:
Pageof 225
ESMO Open|October 23, 2018
Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancerJohan F Vansteenkiste
ESMO Open|December 20, 2021
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trialS Branchoux, C L Sofeu, A-F Gaudin, et al.
ESMO Open|November 28, 2021
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study programV Müller, M Banys-Paluchowski, T W P Friedl, et al.
ESMO Open|December 20, 2021
Letter re: 'Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications'W G Sullivan, A J Hatswell
ESMO Open|March 6, 2021
Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancerC Corti, C Criscitiello
ESMO Open|March 6, 2021
Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indicationsM G Krebs, J-Y Blay, C Le Tourneau, et al.
ESMO Open|March 6, 2021
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 studyB Borelli, E Fontana, M Giordano, et al.
ESMO Open|November 15, 2018
Prognostic Nutritional Index: an easy nutritional screening for patients with head and neck cancer?Paolo Bossi
ESMO Open|September 3, 2023
Comment on redefining authorship in the era of artificial intelligence: balancing ethics, transparency, and progressM Scimeca, R Bonfiglio
ESMO Open|September 3, 2023
Unlocking digitally enabled research in oncology: the time is nowM A Franzoi, E Gillanders, I Vaz-Luis
Pageof 225